These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 20591669)

  • 1. In vivo and in vitro SAR of tetracyclic MAPKAP-K2 (MK2) inhibitors. Part II.
    Revesz L; Schlapbach A; Aichholz R; Dawson J; Feifel R; Hawtin S; Littlewood-Evans A; Koch G; Kroemer M; Möbitz H; Scheufler C; Velcicky J; Huppertz C
    Bioorg Med Chem Lett; 2010 Aug; 20(15):4719-23. PubMed ID: 20591669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo and in vitro SAR of tetracyclic MAPKAP-K2 (MK2) inhibitors. Part I.
    Revesz L; Schlapbach A; Aichholz R; Feifel R; Hawtin S; Heng R; Hiestand P; Jahnke W; Koch G; Kroemer M; Möbitz H; Scheufler C; Velcicky J; Huppertz C
    Bioorg Med Chem Lett; 2010 Aug; 20(15):4715-8. PubMed ID: 20594847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2,4-Diaminopyrimidine MK2 inhibitors. Part II: Structure-based inhibitor optimization.
    Harris CM; Ericsson AM; Argiriadi MA; Barberis C; Borhani DW; Burchat A; Calderwood DJ; Cunha GA; Dixon RW; Frank KE; Johnson EF; Kamens J; Kwak S; Li B; Mullen KD; Perron DC; Wang L; Wishart N; Wu X; Zhang X; Zmetra TR; Talanian RV
    Bioorg Med Chem Lett; 2010 Jan; 20(1):334-7. PubMed ID: 19926477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 4-Anilino-6-phenyl-quinoline inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK2).
    Olsson H; Sjö P; Ersoy O; Kristoffersson A; Larsson J; Nordén B
    Bioorg Med Chem Lett; 2010 Aug; 20(16):4738-40. PubMed ID: 20643547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Facile synthesis of tetracyclic azepine and oxazocine derivatives and their potential as MAPKAP-K2 (MK2) inhibitors.
    Rao AU; Xiao D; Huang X; Zhou W; Fossetta J; Lundell D; Tian F; Trivedi P; Aslanian R; Palani A
    Bioorg Med Chem Lett; 2012 Jan; 22(2):1068-72. PubMed ID: 22182499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 2,4-Diaminopyrimidine MK2 inhibitors. Part I: Observation of an unexpected inhibitor binding mode.
    Argiriadi MA; Ericsson AM; Harris CM; Banach DL; Borhani DW; Calderwood DJ; Demers MD; Dimauro J; Dixon RW; Hardman J; Kwak S; Li B; Mankovich JA; Marcotte D; Mullen KD; Ni B; Pietras M; Sadhukhan R; Sousa S; Tomlinson MJ; Wang L; Xiang T; Talanian RV
    Bioorg Med Chem Lett; 2010 Jan; 20(1):330-3. PubMed ID: 19919896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of selective and orally available spiro-3-piperidyl ATP-competitive MK2 inhibitors.
    Kaptein A; Oubrie A; de Zwart E; Hoogenboom N; de Wit J; van de Kar B; van Hoek M; Vogel G; de Kimpe V; Schultz-Fademrecht C; Borsboom J; van Zeeland M; Versteegh J; Kazemier B; de Roos J; Wijnands F; Dulos J; Jaeger M; Leandro-Garcia P; Barf T
    Bioorg Med Chem Lett; 2011 Jun; 21(12):3823-7. PubMed ID: 21565498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel 1-(2-aminopyrazin-3-yl)methyl-2-thioureas as potent inhibitors of mitogen-activated protein kinase-activated protein kinase 2 (MK-2).
    Lin S; Lombardo M; Malkani S; Hale JJ; Mills SG; Chapman K; Thompson JE; Zhang WX; Wang R; Cubbon RM; O'Neill EA; Luell S; Carballo-Jane E; Yang L
    Bioorg Med Chem Lett; 2009 Jun; 19(12):3238-42. PubMed ID: 19423344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel ATP competitive MK2 inhibitors with potent biochemical and cell-based activity throughout the series.
    Oubrie A; Kaptein A; de Zwart E; Hoogenboom N; Goorden R; van de Kar B; van Hoek M; de Kimpe V; van der Heijden R; Borsboom J; Kazemier B; de Roos J; Scheffers M; Lommerse J; Schultz-Fademrecht C; Barf T
    Bioorg Med Chem Lett; 2012 Jan; 22(1):613-8. PubMed ID: 22119462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitogen-activated protein kinase-activated protein kinase 2 (MAPKAP-K2) as an antiinflammatory target: discovery and in vivo activity of selective pyrazolo[1,5-a]pyrimidine inhibitors using a focused library and structure-based optimization approach.
    Kosugi T; Mitchell DR; Fujino A; Imai M; Kambe M; Kobayashi S; Makino H; Matsueda Y; Oue Y; Komatsu K; Imaizumi K; Sakai Y; Sugiura S; Takenouchi O; Unoki G; Yamakoshi Y; Cunliffe V; Frearson J; Gordon R; Harris CJ; Kalloo-Hosein H; Le J; Patel G; Simpson DJ; Sherborne B; Thomas PS; Suzuki N; Takimoto-Kamimura M; Kataoka K
    J Med Chem; 2012 Aug; 55(15):6700-15. PubMed ID: 22746295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural analysis of an MK2-inhibitor complex: insight into the regulation of the secondary structure of the Gly-rich loop by TEI-I01800.
    Fujino A; Fukushima K; Namiki N; Kosugi T; Takimoto-Kamimura M
    Acta Crystallogr D Biol Crystallogr; 2010 Jan; 66(Pt 1):80-7. PubMed ID: 20057052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pyrrolo-pyrimidones: a novel class of MK2 inhibitors with potent cellular activity.
    Schlapbach A; Feifel R; Hawtin S; Heng R; Koch G; Moebitz H; Revesz L; Scheufler C; Velcicky J; Waelchli R; Huppertz C
    Bioorg Med Chem Lett; 2008 Dec; 18(23):6142-6. PubMed ID: 18945615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-molecular-weight MK2 inhibitors: a tough nut to crack!
    Schlapbach A; Huppertz C
    Future Med Chem; 2009 Oct; 1(7):1243-57. PubMed ID: 21426101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell-penetrating peptides can confer biological function: regulation of inflammatory cytokines in human monocytes by MK2 inhibitor peptides.
    Brugnano JL; Chan BK; Seal BL; Panitch A
    J Control Release; 2011 Oct; 155(2):128-33. PubMed ID: 21600941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-based lead identification of ATP-competitive MK2 inhibitors.
    Barf T; Kaptein A; de Wilde S; van der Heijden R; van Someren R; Demont D; Schultz-Fademrecht C; Versteegh J; van Zeeland M; Seegers N; Kazemier B; van de Kar B; van Hoek M; de Roos J; Klop H; Smeets R; Hofstra C; Hornberg J; Oubrie A
    Bioorg Med Chem Lett; 2011 Jun; 21(12):3818-22. PubMed ID: 21565500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel imidazolopyrimidines as dual PI3-Kinase/mTOR inhibitors.
    Venkatesan AM; Dehnhardt CM; Chen Z; Santos ED; Dos Santos O; Bursavich M; Gilbert AM; Ellingboe JW; Ayral-Kaloustian S; Khafizova G; Brooijmans N; Mallon R; Hollander I; Feldberg L; Lucas J; Yu K; Gibbons J; Abraham R; Mansour TS
    Bioorg Med Chem Lett; 2010 Jan; 20(2):653-6. PubMed ID: 19954970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel 3-aminopyrazole inhibitors of MK-2 discovered by scaffold hopping strategy.
    Velcicky J; Feifel R; Hawtin S; Heng R; Huppertz C; Koch G; Kroemer M; Moebitz H; Revesz L; Scheufler C; Schlapbach A
    Bioorg Med Chem Lett; 2010 Feb; 20(3):1293-7. PubMed ID: 20060294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The discovery of carboline analogs as potent MAPKAP-K2 inhibitors.
    Wu JP; Wang J; Abeywardane A; Andersen D; Emmanuel M; Gautschi E; Goldberg DR; Kashem MA; Lukas S; Mao W; Martin L; Morwick T; Moss N; Pargellis C; Patel UR; Patnaude L; Peet GW; Skow D; Snow RJ; Ward Y; Werneburg B; White A
    Bioorg Med Chem Lett; 2007 Aug; 17(16):4664-9. PubMed ID: 17576063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery and initial SAR of inhibitors of interleukin-1 receptor-associated kinase-4.
    Powers JP; Li S; Jaen JC; Liu J; Walker NP; Wang Z; Wesche H
    Bioorg Med Chem Lett; 2006 Jun; 16(11):2842-5. PubMed ID: 16563752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A three-step protocol for lead optimization: quick identification of key conformational features and functional groups in the SAR studies of non-ATP competitive MK2 (MAPKAPK2) inhibitors.
    Huang X; Zhu X; Chen X; Zhou W; Xiao D; Degrado S; Aslanian R; Fossetta J; Lundell D; Tian F; Trivedi P; Palani A
    Bioorg Med Chem Lett; 2012 Jan; 22(1):65-70. PubMed ID: 22169260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.